The short version of fatty diacid fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-22. Anything still debated is marked as such rather than presented as settled.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
==== Siberia ==== In 1993, a team of Russian archaeologists led by Dr. Natalia Polosmak discovered the Siberian Ice Maiden, a Scytho-Siberian woman, on the Ukok Plateau in the Altai Mountains near the Mongolian border. The mummy was naturally frozen due to the severe climatic conditions of the Siberian steppe. Also known as Princess Ukok, the mummy was dressed in finely detailed clothing and wore an elaborate headdress and jewelry. Alongside her body were buried six decorated horses and a symbolic meal for her last journey. Her left arm and hand were tattooed with animal style figures, including a highly stylized deer. The Ice Maiden has been a source of some recent controversy. The mummy's skin has suffered some slight decay, and the tattoos have faded since the excavation. Some residents of the Altai Republic, formed after the breakup of the Soviet Union, have requested the return of the Ice Maiden, who is currently stored in Novosibirsk in Siberia. Another Siberian mummy, a man, was discovered much earlier in 1929. His skin was also marked with tattoos of two monsters resembling griffins, which decorated his chest, and three partially obliterated images which seem to represent two deer and a mountain goat on his left arm.
== Immunogenicity == When insulin was originally purified from bovine or porcine pancreata, all the proinsulin was not fully removed. When some people used these insulins, the proinsulin may have caused the body to react with a rash, to resist the insulin, or even to make dents or lumps in the skin at the place where the insulin was injected. This can be described as an iatrogenic injury due to slight differences between the proinsulin of different species. Since the late 1970s, when highly purified porcine insulin was introduced, and the level of insulin purity reached 99%, this ceased to be a significant clinical issue. With respect to their influence on insulin pharmacokinetics, moderate concentrations of certain insulin antibodies may be of positive advantage to all diabetics without endogenous insulin secretion (e.g. people with type 1 diabetes) because insulin binding antibodies effectively increase the insulin's clearance rate and distribution space and help to prolong its pharmacological and biological half lives.
The 2012 Essendon Football Club season is the club's 114th season in the Australian Football League (AFL). After a promising start to the season Essendon found themselves second on the ladder with a record of 8 wins and 1 loss (which was by a single point). The season then took an unexpected turn which saw Essendon lose 10 out of the last 13 games and miss the finals. They became the first club to have an 8–1 record and miss finals since Melbourne in the 1971 season. Prior to the final round vice-captain Mark McVeigh announced his retirement from football after 14 season and 232 games at the club. After the Home and Away season completed Essendon captain Jobe Watson was awarded the Brownlow Medal. The highest individual accolade in the AFL. This was later handed back following the drug scandal. The season became notorious for the illegal supplements program that was operated by the club prior to and into the 2012 season. After a three-year investigation, thirty-four players on the 2012 squad were suspected to have been administered the banned peptide Thymosin beta-4 and were suspended for the 2016 season.
=== Recreational use === Sildenafil's popularity with young adults has increased over the years. Sildenafil's brand name, Viagra, is widely recognized in popular culture, and the drug's association with treating erectile dysfunction has led to its recreational use. The reasons behind such use include the belief that the drug increases libido, improves sexual performance, or permanently increases penis size. Studies on the effects of sildenafil when used recreationally are limited, but suggest it has little effect when used by those who do not have erectile dysfunction. In one study, a 25 mg dose was shown to cause no significant change in erectile quality, but did reduce the postejaculatory refractory time. This study also noted a significant placebo effect in the control group. Unprescribed recreational use of sildenafil and other PDE5 inhibitors is noted as particularly high among users of illegal drugs. Sildenafil is sometimes used to counteract the effects of other substances, often illicit. Some users mix it with methylenedioxymethamphetamine (MDMA, ecstasy), other stimulants, or opiates in an attempt to compensate for the common side effect of erectile dysfunction, a combination known as "sextasy", "rockin' and rollin'", "hammerheading", or "trail mix". Mixing it with amyl nitrite, another vasodilator, is particularly dangerous and potentially fatal.
Sources: en.wikipedia.org
==== Nutrient losses ==== Processing foods often involves nutrient losses, which can make it harder to meet the body's needs if these nutrients are not added back through fortification or enrichment. For example, using high heat during processing can cause vitamin C losses. Another example is refined grains, which have less fiber, vitamins and minerals than whole grains. Eating refined grains, such as those found in many processed foods, instead of whole grains may increase the risk for high cholesterol, diabetes and obesity, according to a study published in "The American Journal of Clinical Nutrition" in December 2007.
=== Future developments === When insulin pump technology is combined with a continuous blood glucose monitoring system, the technology seems promising for real time control of the blood sugar level. Currently there are no mature algorithms to automatically control the insulin delivery based on feedback of the blood glucose level. When the loop is closed, the system may function as an artificial pancreas. Insulin pumps are being used for infusing pramlintide (brand name Symlin, or synthetic amylin) with insulin for improved postprandial glycemic control compared to insulin alone. Dual hormone insulin pumps that infuse either insulin or glucagon. In event of hypoglycemia, the glucagon could be triggered to increase the blood glucose. This would be particularly valuable in a closed loop system under the control of a glucose sensor. The Artificial Pancreas, currently in clinical trials for FDA approval, is a recently developed device designed with this technology in mind. Ultrafast insulins are insulins that are absorbed more quickly than the currently available Humalog, Novolog, and Apidra which have a peak at about 60 minutes could be administered. Faster insulin uptake would theoretically coordinate with meals better, and allow faster recovery from hyperglycemia if the insulin infusion is suspended. Biodel is developing an ultrafast insulin
== Bibliography == Cécile Allegri, Claire Brosse, Federico Oldenburg and Hervé Robert, La Pomme de terre, saveurs méditerranéennes, Éditions du Bottin Gourmand, coll. « Les essentiels du goût », 2003, 99 p. (ISBN 2-913306-61-6). Joseph Bonjean, Monographie de la pomme de terre envisagée dans ses rapports agricoles, scientifiques et industriels et comprenant l'histoire générale de la maladie des pommes de terre en 1845, Paris, Germer Baillière, 1846, 306 p. Collective, La Pomme de terre. Histoire et recettes gourmandes, Grenoble, Glénat, 2009, 160 p. (ISBN 2-7234-7319-8). Collective, La Pomme de terre, un tour du Monde en 200 recettes, Geneva, United Nations, 2008, 360 p. (ISBN 92-1-200373-7). Lucienne Desnoues, Toute la pomme de terre, Paris, Mercure de France, 1978, 302 p. Qu Dongyu et Xie Kaiyun, How the Chinese Eat Potatoes, Singapour, World Scientific Publishing Company, 2009, 432 p. (ISBN 981-283-291-2). Jean Ferniot (pref. Joël Robuchon), Chère pomme de terre, First, 1996, 301 p. (ISBN 978-2-87691-327-1). Martine Jolly, Merci M. Parmentier, ou La gloire de la pomme de terre en 200 recettes, Robert Laffont, 1985, 224 p. (ISBN 2-221-04653-6). Mme Mérigot, La Cuisinière républicaine, qui enseigne la manière simple d'accommoder les pommes de terre; avec quelques avis sur les soins nécessaires pour les conserver Archived July 12, 2023, at the Wayback Machine, Paris, Chez Mérigot jeune, 1794–1795, 42 p. C. Monteros, J. Jiménez, Gavilanes, La Magia de la Papa Nativa. Recetario Gastronómico, Quito, INIAP, 2006, 71 p.
=== Self-administration === As opposed to intramuscular or intravenous injections, subcutaneous injections can be easily performed by people with minor skill and training required. The injection sites for self-injection of medication are the same as for injection by a healthcare professional, and the skill can be taught to patients using pictures, videos, or models of the subcutaneous tissue for practice. People who are to self-inject medicine subcutaneously should be trained how to evaluate and rotate the injection site if complications or contraindications arise. Self-administration by subcutaneous injection generally does not require disinfection of the skin outside of a hospital setting as the risk of infection is extremely low, but instead it is recommended to ensure that the site and person's hands are simply clean prior to administration.
=== Selective labeling and tracking of biomolecules === Click chemistry is often employed to attach visualizing tags. In many potential applications, click reactions join a biomolecule and a reporter molecule or other molecular probe, a process called bioconjugation. The possibility of attaching fluorophores and other reporter molecules has made click chemistry a tool for identifying, locating, and characterizing biomolecules. One of the earliest and most important methods in bioconjugation was to express a reporter gene, such as the gene green fluorescent protein (GFP), on the same genetic sequence as a protein of interest. Examples of bioconjugation for labelling include the use of azidocoumarin to label alkyne groups in modified proteins and biomolecules. The fluorophore rhodamine has been coupled onto norbornene, and reacted with tetrazine in living systems. In other cases, SPAAC between a cyclooctyne-modified fluorophore and azide-tagged proteins allowed the selection of these proteins in cell lysates.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.